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Focal adhesion kinase (FAK) is an intracellular kinase that local-
izes to focal adhesions. FAK is overexpressed in human tumours,
and FAK regulates both cellular adhesion and anti-apoptotic
survival signalling. Disruption of FAK function by overexpression
of the FAK C-terminal domain [FAK-CD, analogous to the FRNK
(FAK-related non-kinase) protein] leads to loss of adhesion and
apoptosis in tumour cells. We have shown that overexpression
of an activated form of the Src tyrosine kinase suppressed the
loss of adhesion induced by dominant-negative; adenoviral FAK-
CD and decreased the apoptotic response in BT474 and MCF-7
breast cancer cell lines. This adhesion-dependent apoptosis was
increased by the Src-family kinase inhibitor PP2 {4-amino-5-(4-
chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine}. We have
also shown that expression of activated Src in breast cancer cells
increased the expression of α2-integrin and that overexpression
of α2-integrin suppressed FAK-CD-mediated loss of adhesion.
Our results suggest a model in which Src regulates adhesion and
survival through enhanced expression of the α2-integrin. This
provides a mechanism through which Src promotes cellular
adhesion and alters the adhesive function of FAK.
Key words: apoptosis, cancer, focal adhesion kinase (FAK),
integrin, kinase, Src.
INTRODUCTION
The development of invasive and metastatic cancer requires modu-
lation of adhesion as cells invade their substratum, migrate and
then survive in a new environment. These processes require
protein kinases, which phosphorylate target proteins on a serine/
threonine or tyrosine residue. Focal adhesion kinase (FAK) is a
125 kDa non-receptor tyrosine kinase localized to focal adhesions
[1], which are the contact points between cultured cells and their
underlying substratum, and are sites of intense tyrosine phos-
phorylation [2]. FAK is phosphorylated in response to a number of
stimuli, including clustering of integrins [3] and plating on fibro-
nectin [4,5] and in response to a number of mitogenic agents[6].
FAK is overexpressed in invasive and metastatic tumours [7],
and the FAK gene is also amplified in many types of tumours [8],
suggesting a role for FAK in adhesion or survival in tumour
cells. FAK is associated with a cellular survival signal that is in-
dependent of its role in adhesion. FAK transduces a survival signal
in response to the extracellular matrix that suppresses a p53-
dependent apoptotic response [9]. In tumour cells, attenuation
of FAK expression induces detachment and apoptosis, but non-
transformed cells are less sensitive [10], suggesting that an FAK-
dependent signal is required for tumour cell growth. Furthermore,
an activated form of FAK leads to resistance to anoikis [11], and
FAK degradation is associated with apoptosis [12,13].
FAK function can be disrupted by overexpression of the FAK C-
terminal 360 amino acids. This portion of FAK is produced from
a separate transcript in avian cells [14], and this protein [FRNK
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(FAK-related non-kinase)] [15] inhibits cell spreading and
phosphorylation of FAK, the focal adhesion protein paxillin,
and to a lesser extent, tensin [16,17]. We have exogenously expres-
sed an analogous fragment of human FAK, which we call FAK-
CD (FAK C-terminal domain), and found that FAK-CD causes
cell rounding, loss of adhesion and apoptosis in tumour cells, but
not in normal cells [18–20]. Other groups have also reported that
FAK-CD overexpression does not induce apoptosis in normal cells
[21]. Thus FAK-CD provides a convenient means to inactivate
FAK function and dissect the signalling requirements for FAK in
tumour cells.
FAK was originally identified as a major tyrosine-phosphory-
lated protein in cells transformed by v-Src, and FAK physically
associates with v-Src [22,23]. c-Src is a cytoplasmic tyrosine
kinase containing SH2 and SH3 (Src homology 2 and 3) domains,
which direct protein–protein interactions at its C-terminus [24].
The v-Src protein contains mutations at the N- and C-termini
[25], and an analogous mutation of the C-terminal tyrosine, Tyr527,
renders the Src protein transforming in NIH3T3 cells [26]. Similar
to FAK, Src is overexpressed in breast cancers, colon cancers and
bladder cancers [27–31]. Src can be activated by platelet-derived
growth factor receptor [32], the epidermal growth factor receptor,
and the c-erb-2/neu receptor [33]. Src activation by Neu leads to
attachment-independent growth of human breast epithelial cells
[34]. One model for Src function is that c-Src activation can
bypass the requirement of breast epithelial cells for attachment
and integrin signalling, in addition to contributing to cytoskeleton
rearrangements and increased migration [35,36].
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Src increases tyrosine phosphorylation of FAK and paxillin
[17] and can rescue the detachment of chicken embryo cells from
FAK inhibition [17]. The crucial event in this rescue appears
to be the phosphorylation of paxillin by Src and the binding of
Src to FAK, but the catalytic activity of FAK was not required
[17]. For this reason, FAK was postulated to act as a ‘switchable
adaptor’ that recruits c-Src to phosphorylate paxillin. Therefore
we speculated whether activated c-Src can rescue the detachment
and apoptosis caused by deregulation of FAK in tumour cells.
In the present study, we demonstrate that activated Src causes
morphological changes in BT474 breast cancer cells, rescues the
detachment caused by FAK-CD and leads to decreased apoptosis.
Src increases the tyrosine phosphorylation of FAK and paxillin
and leads to increased expression of α2-integrin. Exogenous ex-
pression of α2-integrin also suppresses loss of adhesion medi-
ated by FAK-CD. These results suggest a novel pathway active
in breast tumour cells, namely the regulation of adhesion and
survival mediated by the concerted action of Src, FAK and α2-
integrin.
EXPERIMENTAL
Cell culture
BT474 and MCF-7 breast ductal carcinoma cells were purchased
from the A.T.C.C. (Manassas, VA, U.S.A.). BT474 cells were
maintained in RPMI 1640 with 10% (v/v) foetal bovine serum,
10 µg/ml insulin and 2 mM L-glutamine. MCF-7 cells were
cultured in Eagle’s minimal essential medium, containing 10%
foetal bovine serum, 10 µg/ml insulin, 1 mM sodium pyruvate
and 0.1 mM non-essential amino acids. Cells were incubated at
37 ◦C in a 5% CO2 atmosphere.
To prepare stable cell lines expressing activated Src and vector
control cells, activated Src (pUSEamp Src-529F; Upstate USA,
Charlottesville, VA, U.S.A.) or the host plasmid (pUSEamp;
Upstate USA) was transfected into BT474 breast cancer cells,
and stable BT474/Src and BT474/vector cell lines were obtained
using selection media containing 500 µg/ml Geneticin (Gibco
BRL, Gaithersburg, MD, U.S.A.). Src expression was confirmed
by Western-blot analysis using an antibody directed to v-Src
(Calbiochem, La Jolla, CA, U.S.A.).
BT474 cells expressing α2-integrin were prepared similarly.
The α2-integrin coding sequence was excised from the plasmid
pSF-α2 (a gift from Dr R. Juliano, University of North Carolina
at Chapel Hill, N.C., U.S.A.) using the restriction endonucleases
XbaI and BamHI, and was cloned into the same sites in the
pcDNA3 plasmid (Invitrogen, Carlsbad, CA, U.S.A.), forming
the pcDNA3-α2-int plasmid. Cells were transfected with the
pcDNA3-α2-int plasmid, and continuously expressing stable cell
lines were identified by Western-blot analysis using an anti-α2-
integrin antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
U.S.A.).
Immunofluorescence staining, Western-blot analysis
and immunoprecipitation
Immunofluorescent staining, Western-blot analysis and immuno-
precipitation were performed as described previously [19].
For immunological analyses, the antibodies used were anti-v-
Src (Calbiochem), anti-FAK 4.47 (Upstate USA), anti-paxillin
(Upstate USA), anti-phosphotyrosine (Upstate USA), anti-FAK
pY397 (Biosource, Camarillo, CA, U.S.A.), anti-tubulin (Sigma)
and anti-α2-integrin (N-19; Santa Cruz Biotechnology). Actin
was stained with BodipyFL-Phallacidin (Molecular Probes). The
pan-Src PP2 inhibitor {4-amino-5-(4-chlorophenyl)-7-(t-butyl)
pyrazolo[3,4-d]pyrimidine} was obtained from Calbiochem
[37,38].
Adenoviral transduction
Adenoviruses containing FAK-CD and LacZ were constructed
and prepared as described previously [19]. Cells were plated
at 1.5 × 106 cells/100 mm culture plate, allowed to attach for
16 h and then infected with Ad-FAK-CD (adenovirus expressing
FAK-CD) or Ad-LacZ (adenovirus expressing lacZ gene) at an
optimal concentration of virus for each cell line. The optimal viral
concentration was determined by the infection of breast cancer
cell lines with different viral concentrations and the viral titre that
produced > 90% cell infectivity was used. The optimal viral titre
was 500 ffu (focus forming units/cell), obtained from the Gene
Therapy Center Virus Vector Core (University of North Carolina
at Chapel Hill). The optimal viral titre caused protein expression
in 100% of the cells without toxic effect checked by X-Gal
(5-bromo-4-chloroindol-3-yl β-D-galactopyranoside) staining for
Ad-LacZ transduction and by haemagglutinin immunostaining
for Ad-FAK-CD infection, as described previously in [19].
Treatment with the Src-family kinase inhibitor PP2
Cells were starved without serum for 1 h and PP2 was added
at 30 µM for 15 min. This optimal PP2 dose was chosen in a
dose–response experiment by blocking Src downstream phos-
phorylation. PP2 was added at 30 µM to the medium for 24 h for
Ad-FAK-CD infection experiments.
Detachment assay
After adenoviral infection, the detached cells were collected and
counted microscopically on a haemocytometer. The attached cells
were harvested by trypsinization and counted. The percentage
of detached cells was calculated by dividing the number of
detached cells by the total number of cells in three independent
experiments.
Apoptosis assay
The detached cells were collected, fixed in 3.7% (v/v) formal-
dehyde in 1 × PBS solution and used for the apoptosis assay.
Apoptosis was detected by Hoechst 33342 staining or TUNEL
(terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labelling) assay using the ApopTag kit (Oncor, Gaithersburg,
MD, U.S.A.) essentially as described in [18,39]. The percentage
of apoptosis in detached cells was calculated as the ratio of
apoptotic detached cells to the total number of detached cells.
The percentage of apoptosis in the total population of cells was
calculated as the ratio of apoptotic cells to the total number of cells.
Apoptotic rate in attached cells was checked by Hoechst 33 342
staining and was equal to zero. For each experiment, 300 cells/
treatment were counted.
PolyHEMA (polyhydroxyethylmethacrylate polymer)-coated tissue
culture dishes
Tissue culture dishes were coated with a film of polyHEMA
(Aldrich Chemical, Milwaukee, WI, U.S.A.), as described by
Valentinis et al. [39]. Briefly, a 12% solution of polyHEMA in
95% (v/v) ethanol was mixed overnight, centrifuged at 2500 rev./
min to remove undissolved particles and diluted 1:10 with
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95% ethanol. Then, 100 mm dishes were coated with 4 ml of
polyHEMA solution and left to dry at room temperature (22 ◦C).
Dishes were washed twice with PBS and once with Hanks
balanced salt solution before use.
RT (reverse transcriptase)–PCR analysis
For analysis of integrin mRNA expression, RT–PCR was per-
formed as described in [40]. The oligonucleotide primers for RT–
PCR were used as described in [40].
Northern-blot analysis
Total RNA was isolated from breast cancer cell lines using the
NucleoSpin II PurificationII Kit according to the manufacturer’s
instructions (Clontech, Palo Alto, CA, U.S.A.). Purified RNA
(10 µg) was separated on denaturing formaldehyde–agarose
gels and transferred on to Zeta-Probe membranes (Bio-Rad
Laboratories) by the capillary transfer method in 20 × SSC buffer
overnight. Prehybridization and hybridization were performed for
1 h at 68 ◦C in Express Hyb hybridization solution (Clontech)
according to the manufacturer’s instructions. Northern blots were
washed with 2 × SSC and 0.05% SDS for 30 min at room
temperature and with 0.1% SSC and 0.1% SDS at 50 ◦C for
40 min. The blot was exposed to an X-ray (Kodak Biomax MS)
film at − 70 ◦C. After stripping, a 32P-labelled β-actin probe was
used for the normalization of the mRNA level.
The hybridization probe for α2-integrin was a 1.8 kb EcoRI–
XbaI fragment isolated from the pcDNA3-α2-integrin plasmid.
The purified fragment was labelled with [α-32P]dCTP (Amersham
Biosciences, Piscataway, NJ, U.S.A.) by random priming with
the High Prime DNA Labelling Kit (Roche Diagnostics,
Indianapolis, IN, U.S.A.) and purified using Microspin G-50
columns (Amersham Biosciences). The probe for actin was pur-
chased from Clontech.
Statistical analysis
The statistical significance of differences between the means for
samples in each assay was assessed by a Student’s t test. P < 0.05
were considered significant.
FACS analysis of integrin expression
Integrin expression was determined by FACS analysis. Cells were
detached with trypsin/EDTA, washed with 1 × PBS/1% BSA
and incubated with an anti-α2-integrin antibody in 1 × PBS/1%
BSA for 1 h on ice. After several washes with PBS, cells were
incubated with a secondary FITC-conjugated antibody for 45 min.
Cells were washed three times with PBS and fixed in 2% (w/v)
paraformaldehyde in PBS. Cells (10 000/sample) were analysed
in FACScan flow cytometer (Becton Dickinson, Mountain View,
CA, U.S.A.). Negative controls were set by incubating cells with
the secondary antibody alone.
RESULTS
Activated c-Src increases cell spreading and tyrosine
phosphorylation of FAK and paxillin in breast cancer cells
We expressed the activated form of Src in BT474 human breast
cancer cells, and Src-expressing cells were isolated and confirmed
Figure 1 Adhesion regulation by activated Src in BT474 breast cancer cells
(A) An activated form of Src was overexpressed in BT474 cells. Cells were transfected with
a control plasmid (pUSE; left lane) or pUSE-Src-Y527F (right lane), and expression was
verified by Western-blot analysis (WB). (B) Src localizes to focal adhesions in BT474/Src
cells. BT474/vector (upper panel) and BT474/Src (lower panel) cells were plated on coverslips
and stained with an antibody to Src. IF, immunofluorescence staining. (C) Increased tyrosine
phosphorylation of FAK and paxillin in BT474/Src cells. BT474/vector (left lanes) or BT474/Src
(right lanes) cells were lysed, immunoprecipitated (IP) with antibodies to FAK (top two panels)
or paxillin (bottom two panels) and subjected to Western-blot analysis (IB) with antibodies
to phosphotyrosine (pTyr; first and third panels), FAK (second panel) and paxillin (fourth
panel).
by Western-blot analysis (Figure 1A, right lane). BT474 cells
express undetectable levels of Src (Figure 1A, left lane) compared
with exogenous Src-mutant-expressing cells (Figure 1A, right
lane), and we will refer to the Src-overexpressing cell line as
BT474/Src and the control cell line as BT474/vector. Src localized
to punctate sites at the cell periphery at the focal adhesions (Fig-
ure 1B, lower panel), and Src-expressing cells had a marked
increase in cell spreading (Figure 1B).
Owing to the increased cell spreading in BT474/Src cells,
we next examined the expression and phosphorylation state of
several downstream targets of Src that mediate cellular adhesion.
Tyrosine phosphorylation of FAK and paxillin was increased
in BT474/Src cells compared with BT474/vector control cells
(Figure 1C, first and third panels), whereas there was no differ-
ence in the expression of the two proteins (Figure 1C, second and
fourth panels). The increased phosphorylation of FAK (Figure 2,
top panel) and paxillin (Figure 2, third panel) was largely de-
creased by treatment of the cells with PP2 (Figure 2, cf. lanes 3
and 4 of the first and third panels). In contrast, FAK and paxillin
phosphorylations were not inhibited by the addition of the control
solvent DMSO (Figure 2, first and third panels, lane 3). These
results indicate that c-Src regulates the phosphorylation of Paxillin
and FAK in breast cancer cells.
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Figure 2 Inhibition of increased tyrosine phosphorylation of FAK and
paxillin in BT474/Src cells by PP2
BT474/Src (lanes 1, 3 and 4) or BT474/vector (lanes 2) cells were lysed and immunoprecipitated
with antibodies to FAK (top two panels) or paxillin (bottom two panels) and subjected to Western-
blot analysis with antibodies to phosphotyrosine (pTyr; first and third panels), FAK (second panel)
and paxillin (fourth panel). In lane 3, BT474/Src cells were treated with DMSO alone, whereas
in lane 4, BT474/Src cells were treated with the same volume of DMSO and PP2.
Activated c-Src suppresses the loss of adhesion mediated
by FAK-CD
Overexpressing the C-terminus of FAK in breast cancer cells
causes a significant loss of adhesion and apoptosis [19,20]. We
introduced the FAK-CD by adenoviral infection, and most of
the infected control cells lost adhesion within 24 h (Figure 3A).
BT474/Src cells showed significantly decreased detachment
compared with BT474/vector cells after 24 h (Figure 3A, 42% for
BT474/Src cells versus 92% for BT474/vector cells; P < 0.05).
Addition of PP2 caused a marked increase in detached BT474/Src
cells (Figure 3A, 66% for Ad-FAK-CD + PP2 cells versus 16%
for control Ad-LacZ + PP2 cells; P < 0.05). Thus Src suppresses
loss of adhesion mediated by inhibition of FAK.
Activated Src suppresses adhesion-dependent apoptosis
in BT474 cells
We have shown previously that inhibition of FAK in BT474 cells
has two distinct effects: disruption of cellular adhesion and
induction of apoptosis. The two are distinct, since BT474 cells
maintained in suspension undergo apoptosis rapidly when treated
with FAK-CD [19]. To test whether Src affected the survival
function of FAK and whether it was dependent on cellular adhe-
sion, we treated BT474/vector and BT474/Src cells with FAK-
CD and harvested detached cells; we then analysed the cells for
apoptosis by TUNEL assay or Hoechst staining. There was no
significant difference in apoptotic rate between detached BT474/
Src cells and BT474/vector control cells after 24 h (67.7% for
BT474/vector versus 52.7% for BT474/Src; P = 0.38) or after
48 h (87.4% for BT474/vector versus 76.9% for BT474/Src;
P = 0.28) after transduction of adenoviral FAK-CD. Next,
BT474 cells were maintained in suspension by growing them
in dishes coated with polyHEMA, to which the cells cannot
attach. Cells were treated with Ad-FAK-CD for 48 h and the
percentage of apoptotic cells was determined by TUNEL assay.
As before, there was no difference in the apoptotic rate between
activated Src cells and vector control cells after transduction of
adenoviral Ad-FAK-CD (43.6% for BT474/Src-Y497F versus
Figure 3 Regulation of adhesion and survival signalling by activated Src
in BT474 cells
(A) Src suppresses loss of adhesion after treatment with the Ad-FAK-CD adenovirus. The
percentage of detached cells 24 h after treatment with the Ad-FAK-CD adenovirus [19] was
determined in triplicate. BT474/Src cells had a considerably decreased rate of detachment
compared with BT474/vector cells. PP2 reverses the ability of Src to suppress Ad-FAK-CD-
mediated loss of adhesion. *P < 0.03 for Ad-FAK-CD-treated BT474/Src cells versus Ad-FAK-
CD-treated BT474/vector cells; **P < 0.02 for Ad-FAK-CD-treated BT474/Src cells with PP2
versus the same without PP2. (B) Src suppresses apoptosis in the total population of cells.
Apoptotic rate was lower in BT474/Src cells and it was increased by PP2. Apoptosis was
determined by TUNEL assay or Hoechst 33342 staining, 24 h after Ad-FAK-CD treatment. The
percentage of apoptotic cells was calculated as the ratio of apoptotic cells to the total number
of cells in three independent experiments in several fields with the fluorescent microscope. For
each experiment, 300 cells/treatment were counted. Bars show the means +− S.E.M. for three
independent experiments. *P < 0.04 for Ad-FAK-CD-treated BT474/Src cells versus Ad-FAK-
CD-treated BT474/vector cells; **P < 0.05 for Ad-FAK-CD-treated BT474/Src cells with PP2
versus the same without PP2.
49.6% for BT474/pUSE; P = 0.08). Thus, when cells detach
or are in suspension, Src cannot affect the survival function
of FAK.
However, when apoptosis was analysed in the total population
of cells treated with Ad-FAK-CD, the apoptotic rate was signi-
ficantly low in BT474/Src cells compared with BT474/vector cells
(18% in BT474/Src versus 62% in BT474/vector cells; P = 0.03)
and was increased to >35% (P < 0.05) by PP2 (Figure 3B).
Our results suggested that Src functions as an adhesion-depen-
dent activator of FAK. To test this, we treated cells with Ad-FAK-
CD and compared BT474/vector and BT474/Src cells that were
adherent or non-adherent for levels of FAK tyrosine phosphory-
lation. As expected, adherent BT474/Src cells had increased levels
of FAK and paxillin phosphorylation (Figure 4, lanes 1 and 2). In
detached cells, both BT474/Src and BT474/vector cells lost FAK
and paxillin tyrosine phosphorylation (Figure 4, first and third
panels, lanes 3 and 4 respectively). Thus Src phosphorylation
of FAK and paxillin is part of an adhesion-dependent signalling
cascade.
We next examined the effect of activated Src on FAK locali-
zation after infection with Ad-FAK-CD. FAK normally localizes
c© 2004 Biochemical Society
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Figure 4 Adhesion-dependent Src-mediated phosphorylation of FAK and
paxillin
BT474/Src (lanes 1 and 3) and BT474/vector (lanes 2 and 4) cells were infected with Ad-
FAK-CD, and the attached (lanes 1 and 2) and detached (lanes 3 and 4) cells were harvested.
Cells were lysed and proteins were immunoprecipitated (IP) with antibodies to FAK (top two
panels) or paxillin (bottom two panels) and subjected to Western-blot analysis with antibodies
to phosphotyrosine (first and third panels), FAK (second panel) and paxillin (fourth panel). The
Src-mediated increase in the phosphorylation of FAK and paxillin tyrosine (first and third panels,
cf. lanes 1 and 2) was not detected in detached cells.
Figure 5 Src-mediated localization of FAK after infection with Ad-FAK-CD
BT474/vector and BT474/Src cells were infected with Ad-FAK-CD and control Ad-LacZ
adenoviruses and immunostained with antibodies to FAK. Representative fields are shown.
Most of the BT474/vector cells had rounded morphology and were detached (Figure 3A), and
FAK was displaced from focal adhesions after Ad-FAK-CD infection. In contrast, BT474/Src
cells expressed increased attachment (Figure 3A), and FAK localized at focal adhesions after
Ad-FAK-CD treatment.
to punctate focal adhesion sites at the cell periphery, and after
infection with Ad-FAK-CD, FAK is displaced from these sites
in BT474 vector cells versus Ad-LacZ control cells (Figure 5,
left panels). In BT474/Src cells treated with Ad-FAK-CD, FAK
remained at focal adhesions (Figure 5, right panels). Thus Src
regulates the localization of FAK after infection with the Ad-
FAK-CD adenovirus in BT474 cells.
Activated Src causes enhanced adhesion and suppressed
apoptosis in MCF-7 cells
Breast cancer cell lines are highly heterogeneous, and owing to
increased genome instability in cancer cells, it is preferable to an-
alyse cellular phenotypes in different cell lines. We transfected the
pUSE control plasmid or pUSE-Src-Y527F into MCF-7 breast
cancer cells, established stable transfectants and verified over-
expression of Src by Western-blot analysis (Figure 6A, upper
panel), with vinculin as a control for loading (Figure 6A,
lower panel). Similar to BT474 cells, MCF-7/Src cells exhibited
increased phosphorylation of FAK and paxillin (Figure 6B, first
and third panels) and a flattened morphology (Figure 6C,
top panels).
The activated, Tyr397-phosphorylated form of FAK was in-
creased in MCF-7/Src cells (Figure 6C, left and right panels).
Actin was stained in MCF-7/vector and MCF-7/Src cells (Fig-
ure 6C, top panels) as was the Tyr397-phosphorylated form of
FAK (Figure 6C, middle panels). Activated FAK co-localized with
actin at focal adhesions when images were merged (Figure 6C,
bottom panels).
The activated, Tyr397-phosphorylated form of FAK was in-
creased in MCF-7/Src cells (Figure 7A, lanes 1 and 2). Src over-
expression resulted in increased activity of FAK in attached cells
infected with Ad-FAK-CD (Figure 7A, lane 4) compared with
BT474/vector cells (Figure 7A, lane 3). When detached, both
cell lines infected with Ad-FAK-CD expressed inactive FAK
(Figure 7A).
As for BT474 cells, Src overexpression decreased loss of
adhesion after infection with the FAK-CD-expressing adenovirus
(Figure 7B). Similar to BT474 cells, the adhesive effects of Src
were reversed with PP2 (Figure 7B), whereas PP2 had minimal
effect on detachment in the control cells infected with Ad-LacZ
(Figure 7B). In detached cells, Src was not capable of affecting
the survival of MCF-7/Src cells infected with Ad-FAK-CD, as in
BT474/Src cells. In contrast, Ad-FAK-CD-induced apoptosis was
suppressed in the total population of MCF-7/Src cells compared
with MCF-7/vector cells, and the apoptotic rate was significantly
increased by PP2 (Figure 7C). Thus the ability of Src to protect
cells from loss of adhesion and adhesion-dependent apoptosis
after FAK inhibition is not specific to BT474/Src cells, but was
also observed in another cell line, MCF-7/Src.
Src overexpression leads to increased α2-integrin expression
One potential mechanism for the increased adhesion in c-Src-
Y527F-overexpressing breast cancer cells is the increased expres-
sion of cellular adhesion molecules. For this reason, we ana-
lysed the expression of six different integrins in BT474/vector
and BT474/Src cells by RT–PCR. BT474/Src cells had signi-
ficantly increased expression of α2-integrin, whereas the expres-
sion levels of α1-, α5-, αV-, β1- or β3-integrins were not affected
(Figure 8A). Increased α2-integrin expression was confirmed by
two additional methods, namely Northern-blot analysis in both
BT474 and MCF-7 cells (Figure 8B) and Western-blot analysis
(Figure 8C). We performed FACS analysis to examine whether
α2-integrin is expressed on the cell surface (Figure 8D). Src-
overexpressing cells increased cell-surface expression of α2-
integrin compared with control vector cells (Figure 8D). The
increased α2-integrin expression was significantly decreased in
both BT474/Src and MCF-7/Src cells by PP2 (Figure 8B, lanes 3
and 7), whereas the PP2 solvent DMSO had no inhibitory effect
(Figure 8B, lanes 4 and 8). Thus, in two different breast cancer cell
lines, Src overexpression led to increased α2-integrin expression
at the RNA and protein levels.
To test the effects of α2-integrin overexpression on FAK-
mediated adhesion, we transfected BT474 cells with the plasmid
pcDNA3-α2-int and selected stably expressing clones. The cell
line that stably overexpressed the α2-integrin protein was iden-
tified by Western-blot analysis (Figure 9A, lane 1). By immuno-
staining analysis, we observed overexpression of α2-integrin on
the cell surface in BT474/α2-int cells compared with control
vector cells (Figure 9B). BT474/α2-int cells had a decreased rate
of detachment on exposure to the FAK-CD adenovirus (41.4%
versus 91.7% in BT474/vector cells; P < 0.01; Figure 9C). Thus
α2-integrin overexpression leads to resistance to loss of adhesion
after infection with the FAK-CD adenovirus. These experiments
c© 2004 Biochemical Society
564 H. B. Park and others
Figure 6 Increased phosphorylation of FAK and paxillin and enhanced cellular adhesion in MCF-7/Src cells
(A) MCF-7 breast cancer cells were transfected with the plasmid pUSE (vector) or pUSE-Src-Y497F (Src). Expression of Src was analysed with a monoclonal antibody to Src (upper panel), with
vinculin as a control for loading (lower panel). (B) Increased tyrosine phosphorylation of FAK and paxillin in MCF-7/Src cells. MCF-7/vector (left lanes) or MCF-7/Src (right lanes) were lysed and
immunoprecipitated with antibodies to FAK (top two panels) or paxillin (bottom two panels) and subjected to Western-blot analysis with antibodies to phosphotyrosine (first and third panels), FAK
(second panel) and paxillin (fourth panel). (C) Activated FAK localizes to focal adhesions in MCF-7/Src cells. MCF-7/vector (left panels) and MCF-7/Src (right panels) cells were stained for actin (top
panels) or Tyr397-phosphorylated FAK (middle panels) and the staining patterns were merged (bottom panels). MCF-7/Src cells had increased activation of FAK (Tyr397-phosphorylated FAK) versus
MCF-7/vector cells. Whereas activated FAK stained in an evenly distributed pattern in MCF-7/vector cells (bottom left panel), FAK localized to brightly clustered focal adhesion sites (co-localized
with actin) in MCF-7/Src cells (bottom right panel).
provide evidence that α2-integrin contributes to pro-adhesive
effects in Src-overexpressing cells.
DISCUSSION
FAK expression is increased in a variety of human tumours,
and inhibition of FAK leads to loss of adhesion and apoptosis
that is specific to tumour cells. However, the adhesion signalling
pathways affected by FAK in tumours are poorly understood.
In addition, it was not clear whether FAK-mediated survival
signalling occurred through the same pathway through which FAK
regulated adhesion in tumours. Our results clearly demonstrate
that FAK-mediated survival signalling is dependent on adhesion in
Src-overexpressing breast cancer cell lines, and that Src enhances
the adhesive function by increasing the expression of adhesive α2-
integrin. We had shown previously that inhibition of FAK leads
to apoptosis even under conditions in which cells were deprived of
adhesion [19]. In the present study, we have developed a system
in which the adhesive function of FAK is hyperactivated, and
the anti-apoptotic function in detached cells is unaffected, but
in the total population of cells it suppressed apoptosis. The Ad-
FAK-CD-induced apoptosis was decreased by overexpression of
activated Src and hyperactivation of FAK owing to increased
adhesion. The increased tyrosine phosphorylation of FAK and
paxillin and the increased α2-integrin expression may function
in stabilizing the focal adhesions and localization of FAK at
focal adhesion sites. Furthermore, the modulation of α2-integrin
expression by the Src inhibitor PP2 suggests a mechanism for
the role of Src in regulating integrin-dependent focal adhesion.
Interestingly, MCF-7/Src cells were more sensitive to FAK-
CD + PP2-induced apoptosis compared with BT474/Src cells.
This may be explained by the more robust Src-dependent down-
stream signalling in MCF-7/Src cells compared with BT474/Src
cells and the complete abrogation of α2-integrin expression by
PP2 in MCF-7/Src cells. Alternatively, there may be other cell-
type-specific mechanisms to explain the difference. These results
are similar to the findings of Windham et al. [41], demonstrating
that enhanced expression of activated Src increases resistance to
anoikis in human colon tumour cell lines.
We have provided a potential mechanism through which acti-
vated Src leads to increased adhesion and the increased tran-
scription of α2-integrin. Furthermore, α2-integrin expression was
capable of suppressing the loss of adhesion caused by inhibition
of FAK function. α2-Integrin has been linked to increased mi-
gration and adhesion in breast cancer cells [42] in a manner
that requires the p38 MAPK (mitogen-activated protein kinase)
[43]. α2-Integrin contributes to robust activation of intracellular
signalling [44] and cell-cycle progression [45]. Thus enhanced
adhesion is consistent with known phenotypes associated with
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Figure 7 Loss of FAK phosphorylation after detachment in Ad-FAK-CD-
treated MCF-7 cells
(A) MCF-7/vector (lanes 1, 3, 5 and 7 from the left) and MCF-7/Src (lanes 2, 4 and 6 from
the left) cells were treated with Ad-LacZ (lanes 1 and 2) or Ad-FAK-CD (lanes 3–7), and FAK
Tyr397 phosphorylation (top panel), FAK expression (middle panel) and tubulin expression
(bottom panel) were determined by Western-blot analysis. FAK phosphorylation was high
in attached MCF-7/vector and MCF-7/Src cells (lanes 1 and 2), but was dramatically
decreased in cells that lost adhesion (lanes 3–7). (B) Src increases adhesion and adhesion-
dependent survival in MCF-7/Src cells. Adhesion of MCF-7/Src and MCF-7/vector cells infected
with Ad-FAK-CD and control Ad-LacZ was analysed as in Figure 3(C). Activated Src caused
increased adhesion of MCF-7/Src cells after Ad-FAK-CD infection compared with control
vector cells (*P < 0.05 for MCF-7/Src + Ad-FAK-CD versus MCF-7/vector + Ad-FAK-CD),
reversed by PP2 (**P < 0.05 for MCF-7/Src + Ad-FAK-CD + PP2 versus MCF-7/Src + Ad-
LacZ + PP2). (C) Activated Src causes inhibition of apoptosis in the total population of MCF-
7/Src cells. Apoptosis was analysed as in Figure 3(B). Apoptosis is suppressed in MCF-7/Src
cells compared with MCF-7/vector cells, and is reversed by PP2. *P < 0.02 for Ad-FAK-CD-
treated MCF-7/Src cells versus Ad-LacZ-treated MCF-7/vector cells; **P < 0.005 for Ad-FAK-
CD-treated MCF-7/Src cells with PP2 versus the same without PP2. Bars show means +− S.E.M.
for three independent experiments.
increased expression of α2-integrin. However, we note that in
some non-tumourigenic breast cell lines [46], Erb-B2 (erythro-
blastic leukaemia viral oncogene homologue 2) leads to decreased
α2-integrin expression, indicating that the pathways regulat-
ing α2-integrin expression are complex and may vary between
cell lines.
Figure 8 Increased α2-integrin expression by activated Src
(A) RT–PCR of cDNA from BT474/vector (left lanes) and BT474/Src (right lanes) cells
amplified with primers to the indicated integrins (top six panels) or glyceraldehyde-3-phosphate
dehydrogenase (bottom panel) as a loading control. BT474/Src cells had highly increased
expression of α2-integrin (fourth panel). (B) Northern-blot analysis of α2-integrin expression.
RNA was purified from the indicated cell lines and visualized with ethidium bromide (bottom
panel) or transferred on to nylon membranes and probed for β-actin (middle panel) or α2-
integrin (top panel). In lanes 3 and 7, cells were treated with PP2, whereas cells in lanes 4 and
8 were treated with an equal concentration of the PP2 carrier DMSO. Activated Src led to in-
creased transcription of α2-integrin that was reversed with PP2. (C) The α2-integrin protein is
increased in Src-expressing breast cancer cells. The indicated cell lines were lysed and subjected
to Western-blot analysis with an antibody to α2-integrin (upper panel) or β-actin (lower panel).
(D) FACS analysis of cell-surface α2-integrin expression in BT474/vector and BT474/Src cells.
The y-axis represents cell number and the logarithmic x-axis represents FITC-fluorescence
intensity in arbitrary units and corresponds to the α2-integrin expression on the cell surface.
The expression of α2-integrin was increased in BT474/Src cells compared with BT474/vector
cells. Experiments were repeated three times with the same result and the representative result
is shown.
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Figure 9 Inhibition of detachment by α2-integrin overexpression in Ad-
FAK-CD-infected BT474 cells
(A) α2-Integrin was overexpressed in BT474 cells. BT474 cells transfected with plasmids
directing expression of α2-integrin (left lane), a control plasmid (middle lane) or an Src-
expressing plasmid were subjected to Western-blot analysis for α2-integrin. Expression of
α2-integrin-transfected cells was increased in α2-integrin-transfected cells (left lane) and
BT474/Src cells (right lane). (B) Overexpression ofα2-integrin on the cell surface inα2-integrin-
transfected BT474 and BT474/Src cells. Immunofluorescence staining (IF) was performed with
an anti-α2-integrin monoclonal antibody and an FITC-conjugated secondary antibody. The
images are representative of three separate experiments. (C) α2-Integrin expression rescues
detachment in Ad-FAK-CD-treated cells. BT474/vector (left bar) and BT474/α2-integrin (right
bar) cells were infected with the Ad-FAK-CD adenovirus, and detached cells were counted
in triplicate. Detachment of Ad-FAK-CD-treated BT474/α2-integrin cells was significantly
decreased compared with BT474/vector cells (*P < 0.008). Error bars indicate S.D. The results
are representative of three independent experiments.
Src kinase activated α2-integrin expression most probably
through increased phosphorylation of transcription factors. Some
of the transcription factor-binding sites (AP-1, AP-2 and six SP-1
sites) for the gene encoding α2-integrin are characterized [47]
and the upstream regulators of α2-integrin expression are known
in some detail. In fibroblasts, platelet-derived growth factor drives
the expression of α2-integrin mRNA, and its promoter induction
requires the function of protein kinase C-ζ , which indicates that
phosphorylation events are required for promoter-directed tran-
scription of α2-integrin [48]. Expression of α2-integrin is also
activated by nuclear factor κB through an indirect mechanism
[49]. Interestingly, Src activation has been linked to nuclear factor
κB activation [50–53], suggesting a mechanism through which
activated Src could enhance the expression of α2-integrin.
We have shown that FAK is overexpressed in a number of
tumour types, including breast cancer [54–57], and this finding
has been confirmed by other groups in different tumour systems
[8,58]. Src is also overexpressed in a number of tumour types,
including breast and colon cancers [41,59]. Thus Src and FAK
can co-operate to regulate adhesion and survival in tumours. In
the present study, we have shown that overexpression of Src led
to increased α2-integrin, which is reversed by PP2. This is the
first step to study further the Src-dependent regulation of integrin
expression leading to mediation of downstream survival signal-
ling. The present study shows a novel mechanism of adhesion-
dependent survival in breast cancer cell lines.
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